EGFR and cancer: Among the top 20 signaling pathways, PI3K-Akt signaling pathway (degree = 10), EGFR tyrosine kinase inhibitor resistance (degree = 9), hemical carcinogenesis-receptor activation (degree = 9), PD-L1 expression and PD-1 checkpoint pathway in cancer (degree = 9), JAK-STAT signaling pathway (degree = 8), and MicroRNAs in cancer (degree = 8) were specific pathways which may play important roles in the effects of CUR against TNBC.